APO Research
Talk to an analyst

APO RESEARCH · REPORT

Insomnia Medication

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Insomnia Medication Market Outlook and Growth Opportunities 2026

27 December 2025201 pages

Choose your research edition.

Industry ResearchInsomnia Medication Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Insomnia Medication Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Insomnia Medication Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Insomnia Medication Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Insomnia Medication Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Insomnia Medication market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Insomnia Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Insomnia Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Insomnia Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Insomnia Medication market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Insomnia Medication market include Takeda, Eisai, Sanofi, Johnson & Johnson, Merck, Pfizer, Vanda Pharmaceuticals, Somnus Therapeutics and SkyePharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Insomnia Medication market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Insomnia Medication and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Insomnia Medication sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Insomnia Medication market size, projected growth trends, production technologies, key applications, and end-use industries.

Insomnia Medication Segment by Company

Takeda

Eisai

Sanofi

Johnson & Johnson

Merck

Pfizer

Vanda Pharmaceuticals

Somnus Therapeutics

SkyePharma

Purdue Pharma

Pernix Therapeutics

Paratek Pharmaceuticals

Neurim

Minerva Neurosciences

Meda

Flynn Pharma

ECR Pharmaceuticals (Valeant)

Dainippon Sumitomo

Astellas

Insomnia Medication Segment by Type

Benzodiazepine Receptor Agonists

Nonbenzodiazepine Receptor Agonists

The Selective Melatonin Receptor Agonist Ramelteon

Sedating Antidepressants

Insomnia Medication Segment by Application

Adults

Kids

Insomnia Medication Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Insomnia Medication status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Insomnia Medication market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Insomnia Medication significant trends, drivers, influence factors in global and regions.

6. To analyze Insomnia Medication competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Insomnia Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Insomnia Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Insomnia Medication.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Insomnia Medication market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Insomnia Medication industry.

Chapter 3: Detailed analysis of Insomnia Medication manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Insomnia Medication in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Insomnia Medication in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Insomnia Medication Industry Trends Table 2. Insomnia Medication Industry Drivers Table 3. Insomnia Medication Industry Opportunities and Challenges Table 4. Insomnia Medication Industry Restraints Table 5. Global Insomnia Medication Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Insomnia Medication Revenue Share by Company (2021-2026) Table 7. Global Insomnia Medication Sales Volume by Company (W Pcs) & (2021-2026) Table 8. Global Insomnia Medication Sales Volume Share by Company (2021-2026) Table 9. Global Insomnia Medication Average Price (US$/Pcs) of Company (2021-2026) Table 10. Global Insomnia Medication Company Ranking, (2024-2026) & (USD Million) Table 11. Global Insomnia Medication Key Company Manufacturing Base & Headquarters Table 12. Global Insomnia Medication Company, Product Type & Application Table 13. Global Insomnia Medication Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Insomnia Medication by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Benzodiazepine Receptor Agonists Table 18. Significant Companies of Nonbenzodiazepine Receptor Agonists Table 19. Significant Companies of The Selective Melatonin Receptor Agonist Ramelteon Table 20. Significant Companies of Sedating Antidepressants Table 21. Global Insomnia Medication Sales Volume by Type 2021 VS 2025 VS 2032 (W Pcs) Table 22. Global Insomnia Medication Sales Volume by Type (2021-2026) & (W Pcs) Table 23. Global Insomnia Medication Sales Volume by Type (2027-2032) & (W Pcs) Table 24. Global Insomnia Medication Sales Volume Share by Type (2021-2026) Table 25. Global Insomnia Medication Sales Volume Share by Type (2027-2032) Table 26. Global Insomnia Medication Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Insomnia Medication Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Insomnia Medication Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Insomnia Medication Sales Value Share by Type (2021-2026) Table 30. Global Insomnia Medication Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Adults Table 32. Significant Companies of Kids Table 33. Global Insomnia Medication Sales Volume by Application 2021 VS 2025 VS 2032 (W Pcs) Table 34. Global Insomnia Medication Sales Volume by Application (2021-2026) & (W Pcs) Table 35. Global Insomnia Medication Sales Volume by Application (2027-2032) & (W Pcs) Table 36. Global Insomnia Medication Sales Volume Share by Application (2021-2026) Table 37. Global Insomnia Medication Sales Volume Share by Application (2027-2032) Table 38. Global Insomnia Medication Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Insomnia Medication Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Insomnia Medication Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Insomnia Medication Sales Value Share by Application (2021-2026) Table 42. Global Insomnia Medication Sales Value Share by Application (2027-2032) Table 43. Global Insomnia Medication Sales by Region: 2021 VS 2025 VS 2032 (W Pcs) Table 44. Global Insomnia Medication Sales by Region (2021-2026) & (W Pcs) Table 45. Global Insomnia Medication Sales Market Share by Region (2021-2026) Table 46. Global Insomnia Medication Sales by Region (2027-2032) & (W Pcs) Table 47. Global Insomnia Medication Sales Market Share by Region (2027-2032) Table 48. Global Insomnia Medication Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Insomnia Medication Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Insomnia Medication Sales Value Share by Region (2021-2026) Table 51. Global Insomnia Medication Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Insomnia Medication Sales Value Share by Region (2027-2032) Table 53. Global Insomnia Medication Market Average Price (US$/Pcs) by Region (2021-2026) Table 54. Global Insomnia Medication Market Average Price (US$/Pcs) by Region (2027-2032) Table 55. Global Insomnia Medication Sales by Country: 2021 VS 2025 VS 2032 (W Pcs) Table 56. Global Insomnia Medication Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Insomnia Medication Sales by Country (2021-2026) & (W Pcs) Table 58. Global Insomnia Medication Sales Market Share by Country (2021-2026) Table 59. Global Insomnia Medication Sales by Country (2027-2032) & (W Pcs) Table 60. Global Insomnia Medication Sales Market Share by Country (2027-2032) Table 61. Global Insomnia Medication Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Insomnia Medication Sales Value Market Share by Country (2021-2026) Table 63. Global Insomnia Medication Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Insomnia Medication Sales Value Market Share by Country (2027-2032) Table 65. Takeda Company Information Table 66. Takeda Business Overview Table 67. Takeda Insomnia Medication Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 68. Takeda Insomnia Medication Product Portfolio Table 69. Takeda Recent Development Table 70. Eisai Company Information Table 71. Eisai Business Overview Table 72. Eisai Insomnia Medication Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 73. Eisai Insomnia Medication Product Portfolio Table 74. Eisai Recent Development Table 75. Sanofi Company Information Table 76. Sanofi Business Overview Table 77. Sanofi Insomnia Medication Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 78. Sanofi Insomnia Medication Product Portfolio Table 79. Sanofi Recent Development Table 80. Johnson & Johnson Company Information Table 81. Johnson & Johnson Business Overview Table 82. Johnson & Johnson Insomnia Medication Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 83. Johnson & Johnson Insomnia Medication Product Portfolio Table 84. Johnson & Johnson Recent Development Table 85. Merck Company Information Table 86. Merck Business Overview Table 87. Merck Insomnia Medication Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 88. Merck Insomnia Medication Product Portfolio Table 89. Merck Recent Development Table 90. Pfizer Company Information Table 91. Pfizer Business Overview Table 92. Pfizer Insomnia Medication Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 93. Pfizer Insomnia Medication Product Portfolio Table 94. Pfizer Recent Development Table 95. Vanda Pharmaceuticals Company Information Table 96. Vanda Pharmaceuticals Business Overview Table 97. Vanda Pharmaceuticals Insomnia Medication Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 98. Vanda Pharmaceuticals Insomnia Medication Product Portfolio Table 99. Vanda Pharmaceuticals Recent Development Table 100. Somnus Therapeutics Company Information Table 101. Somnus Therapeutics Business Overview Table 102. Somnus Therapeutics Insomnia Medication Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 103. Somnus Therapeutics Insomnia Medication Product Portfolio Table 104. Somnus Therapeutics Recent Development Table 105. SkyePharma Company Information Table 106. SkyePharma Business Overview Table 107. SkyePharma Insomnia Medication Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 108. SkyePharma Insomnia Medication Product Portfolio Table 109. SkyePharma Recent Development Table 110. Purdue Pharma Company Information Table 111. Purdue Pharma Business Overview Table 112. Purdue Pharma Insomnia Medication Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 113. Purdue Pharma Insomnia Medication Product Portfolio Table 114. Purdue Pharma Recent Development Table 115. Pernix Therapeutics Company Information Table 116. Pernix Therapeutics Business Overview Table 117. Pernix Therapeutics Insomnia Medication Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 118. Pernix Therapeutics Insomnia Medication Product Portfolio Table 119. Pernix Therapeutics Recent Development Table 120. Paratek Pharmaceuticals Company Information Table 121. Paratek Pharmaceuticals Business Overview Table 122. Paratek Pharmaceuticals Insomnia Medication Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 123. Paratek Pharmaceuticals Insomnia Medication Product Portfolio Table 124. Paratek Pharmaceuticals Recent Development Table 125. Neurim Company Information Table 126. Neurim Business Overview Table 127. Neurim Insomnia Medication Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 128. Neurim Insomnia Medication Product Portfolio Table 129. Neurim Recent Development Table 130. Minerva Neurosciences Company Information Table 131. Minerva Neurosciences Business Overview Table 132. Minerva Neurosciences Insomnia Medication Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 133. Minerva Neurosciences Insomnia Medication Product Portfolio Table 134. Minerva Neurosciences Recent Development Table 135. Meda Company Information Table 136. Meda Business Overview Table 137. Meda Insomnia Medication Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 138. Meda Insomnia Medication Product Portfolio Table 139. Meda Recent Development Table 140. Flynn Pharma Company Information Table 141. Flynn Pharma Business Overview Table 142. Flynn Pharma Insomnia Medication Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 143. Flynn Pharma Insomnia Medication Product Portfolio Table 144. Flynn Pharma Recent Development Table 145. ECR Pharmaceuticals (Valeant) Company Information Table 146. ECR Pharmaceuticals (Valeant) Business Overview Table 147. ECR Pharmaceuticals (Valeant) Insomnia Medication Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 148. ECR Pharmaceuticals (Valeant) Insomnia Medication Product Portfolio Table 149. ECR Pharmaceuticals (Valeant) Recent Development Table 150. Dainippon Sumitomo Company Information Table 151. Dainippon Sumitomo Business Overview Table 152. Dainippon Sumitomo Insomnia Medication Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 153. Dainippon Sumitomo Insomnia Medication Product Portfolio Table 154. Dainippon Sumitomo Recent Development Table 155. Astellas Company Information Table 156. Astellas Business Overview Table 157. Astellas Insomnia Medication Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 158. Astellas Insomnia Medication Product Portfolio Table 159. Astellas Recent Development Table 160. Key Raw Materials Table 161. Raw Materials Key Suppliers Table 162. Insomnia Medication Distributors List Table 163. Insomnia Medication Customers List Table 164. Research Programs/Design for This Report Table 165. Authors List of This Report Table 166. Secondary Sources Table 167. Primary Sources List of Figures Figure 1. Insomnia Medication Product Image Figure 2. Global Insomnia Medication Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Insomnia Medication Sales Value (2021-2032) & (US$ Million) Figure 4. Global Insomnia Medication Sales (2021-2032) & (W Pcs) Figure 5. Global Insomnia Medication Sales Average Price (US$/Pcs) & (2021-2032) Figure 6. Global Insomnia Medication Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Benzodiazepine Receptor Agonists Image Figure 10. Nonbenzodiazepine Receptor Agonists Image Figure 11. The Selective Melatonin Receptor Agonist Ramelteon Image Figure 12. Sedating Antidepressants Image Figure 13. Global Insomnia Medication Sales Volume by Type (2021 VS 2025 VS 2032) & (W Pcs) Figure 14. Global Insomnia Medication Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Insomnia Medication Sales Volume Share by Type (2021-2032) Figure 16. Global Insomnia Medication Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Insomnia Medication Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Insomnia Medication Sales Value Share by Type (2021-2032) Figure 19. Adults Image Figure 20. Kids Image Figure 21. Global Insomnia Medication Sales Volume by Application (2021 VS 2025 VS 2032) & (W Pcs) Figure 22. Global Insomnia Medication Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Insomnia Medication Sales Volume Share by Application (2021-2032) Figure 24. Global Insomnia Medication Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Insomnia Medication Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Insomnia Medication Sales Value Share by Application (2021-2032) Figure 27. Global Insomnia Medication Sales by Region: 2021 VS 2025 VS 2032 (W Pcs) Figure 28. Global Insomnia Medication Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Insomnia Medication Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Insomnia Medication Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Insomnia Medication Sales Value (2021-2032) & (US$ Million) Figure 32. North America Insomnia Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Insomnia Medication Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Insomnia Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Insomnia Medication Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Insomnia Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Insomnia Medication Sales Value (2021-2032) & (US$ Million) Figure 38. South America Insomnia Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Insomnia Medication Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Insomnia Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Insomnia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Insomnia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Insomnia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Insomnia Medication Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Insomnia Medication Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Benzodiazepine Receptor Agonists
  • Nonbenzodiazepine Receptor Agonists
  • The Selective Melatonin Receptor Agonist Ramelteon
  • Sedating Antidepressants
Applications
  • Adults
  • Kids
Companies covered
  • Takeda
  • Eisai
  • Sanofi
  • Johnson & Johnson
  • Merck
  • Pfizer
  • Vanda Pharmaceuticals
  • Somnus Therapeutics
  • SkyePharma
  • Purdue Pharma
  • Pernix Therapeutics
  • Paratek Pharmaceuticals
  • Neurim
  • Minerva Neurosciences
  • Meda
  • Flynn Pharma
  • ECR Pharmaceuticals (Valeant)
  • Dainippon Sumitomo
  • Astellas

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Insomnia Medication Sales Value (2021-2032)
  4. 1.2.2 Global Insomnia Medication Sales Volume (2021-2032)
  5. 1.2.3 Global Insomnia Medication Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Insomnia Medication Market Dynamics
  1. 2.1 Insomnia Medication Industry Trends
  2. 2.2 Insomnia Medication Industry Drivers
  3. 2.3 Insomnia Medication Industry Opportunities and Challenges
  4. 2.4 Insomnia Medication Industry Restraints
3 Insomnia Medication Market by Company
  1. 3.1 Global Insomnia Medication Company Revenue Ranking in 2025
  2. 3.2 Global Insomnia Medication Revenue by Company (2021-2026)
  3. 3.3 Global Insomnia Medication Sales Volume by Company (2021-2026)
  4. 3.4 Global Insomnia Medication Average Price by Company (2021-2026)
  5. 3.5 Global Insomnia Medication Company Ranking (2024-2026)
  6. 3.6 Global Insomnia Medication Company Manufacturing Base and Headquarters
  7. 3.7 Global Insomnia Medication Company Product Type and Application
  8. 3.8 Global Insomnia Medication Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Insomnia Medication Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Insomnia Medication Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Insomnia Medication Market by Type
  1. 4.1 Insomnia Medication Type Introduction
  2. 4.1.1 Benzodiazepine Receptor Agonists
  3. 4.1.2 Nonbenzodiazepine Receptor Agonists
  4. 4.1.3 The Selective Melatonin Receptor Agonist Ramelteon
  5. 4.1.4 Sedating Antidepressants
  6. 4.2 Global Insomnia Medication Sales Volume by Type
  7. 4.2.1 Global Insomnia Medication Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Insomnia Medication Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Insomnia Medication Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Insomnia Medication Sales Value by Type
  11. 4.3.1 Global Insomnia Medication Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Insomnia Medication Sales Value by Type (2021-2032)
  13. 4.3.3 Global Insomnia Medication Sales Value Share by Type (2021-2032)
5 Insomnia Medication Market by Application
  1. 5.1 Insomnia Medication Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Kids
  4. 5.2 Global Insomnia Medication Sales Volume by Application
  5. 5.2.1 Global Insomnia Medication Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Insomnia Medication Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Insomnia Medication Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Insomnia Medication Sales Value by Application
  9. 5.3.1 Global Insomnia Medication Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Insomnia Medication Sales Value by Application (2021-2032)
  11. 5.3.3 Global Insomnia Medication Sales Value Share by Application (2021-2032)
6 Insomnia Medication Regional Sales and Value Analysis
  1. 6.1 Global Insomnia Medication Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Insomnia Medication Sales by Region (2021-2032)
  3. 6.2.1 Global Insomnia Medication Sales by Region: 2021-2026
  4. 6.2.2 Global Insomnia Medication Sales by Region (2027-2032)
  5. 6.3 Global Insomnia Medication Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Insomnia Medication Sales Value by Region (2021-2032)
  7. 6.4.1 Global Insomnia Medication Sales Value by Region: 2021-2026
  8. 6.4.2 Global Insomnia Medication Sales Value by Region (2027-2032)
  9. 6.5 Global Insomnia Medication Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Insomnia Medication Sales Value (2021-2032)
  12. 6.6.2 North America Insomnia Medication Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Insomnia Medication Sales Value (2021-2032)
  15. 6.7.2 Europe Insomnia Medication Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Insomnia Medication Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Insomnia Medication Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Insomnia Medication Sales Value (2021-2032)
  21. 6.9.2 South America Insomnia Medication Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Insomnia Medication Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Insomnia Medication Sales Value Share by Country, 2025 VS 2032
7 Insomnia Medication Country-level Sales and Value Analysis
  1. 7.1 Global Insomnia Medication Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Insomnia Medication Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Insomnia Medication Sales by Country (2021-2032)
  4. 7.3.1 Global Insomnia Medication Sales by Country (2021-2026)
  5. 7.3.2 Global Insomnia Medication Sales by Country (2027-2032)
  6. 7.4 Global Insomnia Medication Sales Value by Country (2021-2032)
  7. 7.4.1 Global Insomnia Medication Sales Value by Country (2021-2026)
  8. 7.4.2 Global Insomnia Medication Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Insomnia Medication Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Insomnia Medication Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Insomnia Medication Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Insomnia Medication Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Insomnia Medication Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Insomnia Medication Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Insomnia Medication Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Insomnia Medication Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Insomnia Medication Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Insomnia Medication Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Insomnia Medication Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Insomnia Medication Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Insomnia Medication Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Insomnia Medication Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Insomnia Medication Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Insomnia Medication Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Insomnia Medication Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Insomnia Medication Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Insomnia Medication Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Insomnia Medication Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Insomnia Medication Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Insomnia Medication Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Insomnia Medication Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Insomnia Medication Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Insomnia Medication Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Insomnia Medication Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Insomnia Medication Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Insomnia Medication Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Insomnia Medication Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Insomnia Medication Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Insomnia Medication Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Insomnia Medication Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Insomnia Medication Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Eisai
  8. 8.2.1 Eisai Company Information
  9. 8.2.2 Eisai Business Overview
  10. 8.2.3 Eisai Insomnia Medication Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eisai Insomnia Medication Product Portfolio
  12. 8.2.5 Eisai Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Insomnia Medication Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Insomnia Medication Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Insomnia Medication Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Insomnia Medication Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Insomnia Medication Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck Insomnia Medication Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Insomnia Medication Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Insomnia Medication Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Vanda Pharmaceuticals
  38. 8.7.1 Vanda Pharmaceuticals Company Information
  39. 8.7.2 Vanda Pharmaceuticals Business Overview
  40. 8.7.3 Vanda Pharmaceuticals Insomnia Medication Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Vanda Pharmaceuticals Insomnia Medication Product Portfolio
  42. 8.7.5 Vanda Pharmaceuticals Recent Developments
  43. 8.8 Somnus Therapeutics
  44. 8.8.1 Somnus Therapeutics Company Information
  45. 8.8.2 Somnus Therapeutics Business Overview
  46. 8.8.3 Somnus Therapeutics Insomnia Medication Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Somnus Therapeutics Insomnia Medication Product Portfolio
  48. 8.8.5 Somnus Therapeutics Recent Developments
  49. 8.9 SkyePharma
  50. 8.9.1 SkyePharma Company Information
  51. 8.9.2 SkyePharma Business Overview
  52. 8.9.3 SkyePharma Insomnia Medication Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 SkyePharma Insomnia Medication Product Portfolio
  54. 8.9.5 SkyePharma Recent Developments
  55. 8.10 Purdue Pharma
  56. 8.10.1 Purdue Pharma Company Information
  57. 8.10.2 Purdue Pharma Business Overview
  58. 8.10.3 Purdue Pharma Insomnia Medication Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Purdue Pharma Insomnia Medication Product Portfolio
  60. 8.10.5 Purdue Pharma Recent Developments
  61. 8.11 Pernix Therapeutics
  62. 8.11.1 Pernix Therapeutics Company Information
  63. 8.11.2 Pernix Therapeutics Business Overview
  64. 8.11.3 Pernix Therapeutics Insomnia Medication Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Pernix Therapeutics Insomnia Medication Product Portfolio
  66. 8.11.5 Pernix Therapeutics Recent Developments
  67. 8.12 Paratek Pharmaceuticals
  68. 8.12.1 Paratek Pharmaceuticals Company Information
  69. 8.12.2 Paratek Pharmaceuticals Business Overview
  70. 8.12.3 Paratek Pharmaceuticals Insomnia Medication Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Paratek Pharmaceuticals Insomnia Medication Product Portfolio
  72. 8.12.5 Paratek Pharmaceuticals Recent Developments
  73. 8.13 Neurim
  74. 8.13.1 Neurim Company Information
  75. 8.13.2 Neurim Business Overview
  76. 8.13.3 Neurim Insomnia Medication Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Neurim Insomnia Medication Product Portfolio
  78. 8.13.5 Neurim Recent Developments
  79. 8.14 Minerva Neurosciences
  80. 8.14.1 Minerva Neurosciences Company Information
  81. 8.14.2 Minerva Neurosciences Business Overview
  82. 8.14.3 Minerva Neurosciences Insomnia Medication Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Minerva Neurosciences Insomnia Medication Product Portfolio
  84. 8.14.5 Minerva Neurosciences Recent Developments
  85. 8.15 Meda
  86. 8.15.1 Meda Company Information
  87. 8.15.2 Meda Business Overview
  88. 8.15.3 Meda Insomnia Medication Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Meda Insomnia Medication Product Portfolio
  90. 8.15.5 Meda Recent Developments
  91. 8.16 Flynn Pharma
  92. 8.16.1 Flynn Pharma Company Information
  93. 8.16.2 Flynn Pharma Business Overview
  94. 8.16.3 Flynn Pharma Insomnia Medication Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Flynn Pharma Insomnia Medication Product Portfolio
  96. 8.16.5 Flynn Pharma Recent Developments
  97. 8.17 ECR Pharmaceuticals (Valeant)
  98. 8.17.1 ECR Pharmaceuticals (Valeant) Company Information
  99. 8.17.2 ECR Pharmaceuticals (Valeant) Business Overview
  100. 8.17.3 ECR Pharmaceuticals (Valeant) Insomnia Medication Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 ECR Pharmaceuticals (Valeant) Insomnia Medication Product Portfolio
  102. 8.17.5 ECR Pharmaceuticals (Valeant) Recent Developments
  103. 8.18 Dainippon Sumitomo
  104. 8.18.1 Dainippon Sumitomo Company Information
  105. 8.18.2 Dainippon Sumitomo Business Overview
  106. 8.18.3 Dainippon Sumitomo Insomnia Medication Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Dainippon Sumitomo Insomnia Medication Product Portfolio
  108. 8.18.5 Dainippon Sumitomo Recent Developments
  109. 8.19 Astellas
  110. 8.19.1 Astellas Company Information
  111. 8.19.2 Astellas Business Overview
  112. 8.19.3 Astellas Insomnia Medication Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Astellas Insomnia Medication Product Portfolio
  114. 8.19.5 Astellas Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Insomnia Medication Value Chain Analysis
  2. 9.1.1 Insomnia Medication Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Insomnia Medication Sales Mode & Process
  6. 9.2 Insomnia Medication Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Insomnia Medication Distributors
  9. 9.2.3 Insomnia Medication Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst